Data as of Dec 19
| -0.71 / -4.36%|
The 4 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 49.50, with a high estimate of 62.00 and a low estimate of 44.00. The median estimate represents a +217.92% increase from the last price of 15.57.
The current consensus among 4 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.